• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血浆衍生外泌体中的 PD-L1 mRNA 表达与黑色素瘤和 NSCLC 患者对抗 PD-1 抗体的反应相关。

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.

机构信息

Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Medical Oncology Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

出版信息

Br J Cancer. 2018 Mar 20;118(6):820-824. doi: 10.1038/bjc.2018.9. Epub 2018 Mar 6.

DOI:10.1038/bjc.2018.9
PMID:29509748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5886129/
Abstract

This corrects the article DOI: 10.1038/bjc.2017.85.

摘要

本文更正了文章的 DOI：10.1038/bjc.2017.85。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b8/5886129/9199b0e3da14/bjc20189f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b8/5886129/9199b0e3da14/bjc20189f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44b8/5886129/9199b0e3da14/bjc20189f1.jpg

相似文献

1
PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.血浆衍生外泌体中的 PD-L1 mRNA 表达与黑色素瘤和 NSCLC 患者对抗 PD-1 抗体的反应相关。
Br J Cancer. 2018 Mar 20;118(6):820-824. doi: 10.1038/bjc.2018.9. Epub 2018 Mar 6.
2
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.PD-1 阻断治疗非小细胞肺癌、头颈部鳞状细胞癌和黑色素瘤后的免疫相关基因表达谱分析。
Cancer Res. 2017 Jul 1;77(13):3540-3550. doi: 10.1158/0008-5472.CAN-16-3556. Epub 2017 May 9.
3
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.肿瘤类型中 PD-L1 的研究、其在接受免疫检查点抑制剂治疗的患者中的差异表达及其预测价值。
Clin Cancer Res. 2017 Aug 1;23(15):4270-4279. doi: 10.1158/1078-0432.CCR-16-3146. Epub 2017 Feb 21.
4
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient.非小细胞肺癌患者接受纳武单抗治疗期间出现的与抗程序性死亡蛋白1相关的冷球蛋白血症。
Ann Oncol. 2017 Jun 1;28(6):1405-1406. doi: 10.1093/annonc/mdx126.
5
PD-1 Blockers.PD-1 抑制剂。
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.
6
The impact of corticosteroid use during anti-PD1 treatment.抗PD-1治疗期间使用皮质类固醇的影响。
J Oncol Pharm Pract. 2020 Jun;26(4):814-822. doi: 10.1177/1078155219872786. Epub 2019 Sep 7.
7
Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.可溶性程序性细胞死亡配体 1 作为纳武利尤单抗治疗非小细胞肺癌的新型生物标志物。
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1. doi: 10.1016/j.cllc.2018.04.014. Epub 2018 May 5.
8
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.抗PD-1疗法治疗病毒性肝炎患者转移性黑色素瘤和非小细胞肺癌的安全性和疗效：病例系列
Melanoma Res. 2018 Apr;28(2):155-158. doi: 10.1097/CMR.0000000000000434.
9
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.不同程序性死亡配体-1 诊断检测试剂用于非小细胞肺癌不同蛋白表达截断值时的一致性。
Clin Cancer Res. 2017 Jul 15;23(14):3585-3591. doi: 10.1158/1078-0432.CCR-16-2375. Epub 2017 Jan 10.
10
Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.与化疗相比，PD-1/PD-L1抑制剂在晚期癌症患者中的安全性和耐受性：一项荟萃分析。
Oncologist. 2017 Apr;22(4):470-479. doi: 10.1634/theoncologist.2016-0419. Epub 2017 Mar 8.

引用本文的文献

1
Nanotechnology-driven platforms for extracellular vesicle analysis in tumor immunotherapy.用于肿瘤免疫治疗中细胞外囊泡分析的纳米技术驱动平台。
Front Immunol. 2025 Jul 30;16:1632378. doi: 10.3389/fimmu.2025.1632378. eCollection 2025.
2
Exosomal PD-L1 detection in cancer predictive biomarker for response to immune checkpoint blockade therapy.癌症中检测外泌体程序性死亡受体配体1作为免疫检查点阻断疗法反应的预测生物标志物。
Front Immunol. 2025 Jul 3;16:1603855. doi: 10.3389/fimmu.2025.1603855. eCollection 2025.
3
Molecular markers for the efficacy of neoadjuvant immunotherapy for head and neck squamous cell carcinoma.

本文引用的文献

1
Programmed Death Ligand 1 Expression in Paired Non-Small Cell Lung Cancer Tumor Samples.程序性死亡配体 1 在配对的非小细胞肺癌肿瘤样本中的表达。
Clin Lung Cancer. 2017 Nov;18(6):e473-e479. doi: 10.1016/j.cllc.2017.04.008. Epub 2017 Apr 24.
2
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.血浆衍生外泌体 RNA 中雄激素受体剪接变体 7 的检测强烈预测转移性前列腺癌患者对激素治疗的耐药性。
Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10.
3
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
头颈部鳞状细胞癌新辅助免疫治疗疗效的分子标志物
Front Oncol. 2025 Jun 23;15:1586130. doi: 10.3389/fonc.2025.1586130. eCollection 2025.
4
Exosomal proteins: new targets for early diagnosis and treatment of cancer.外泌体蛋白：癌症早期诊断与治疗的新靶点。
Front Immunol. 2025 Jun 19;16:1613494. doi: 10.3389/fimmu.2025.1613494. eCollection 2025.
5
Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer.预测非小细胞肺癌免疫治疗疗效的生物标志物的最新进展。
Front Immunol. 2025 May 8;16:1554871. doi: 10.3389/fimmu.2025.1554871. eCollection 2025.
6
Development of LncRNA Biomarkers in Extracellular Vesicle of Amniotic Fluid Associated with Antenatal Hydronephrosis.与产前肾积水相关的羊水细胞外囊泡中长链非编码RNA生物标志物的研究进展
Biomedicines. 2025 Mar 8;13(3):668. doi: 10.3390/biomedicines13030668.
7
Plasma cell-free RNA PD-L1 or tissue PD-L1 protein expression and outcomes with first-line immunotherapy in metastatic non-small cell lung cancer.血浆游离RNA中PD-L1或组织中PD-L1蛋白表达与转移性非小细胞肺癌一线免疫治疗的疗效
J Liq Biopsy. 2023 Dec 4;3:100130. doi: 10.1016/j.jlb.2023.100130. eCollection 2024 Mar.
8
Biomarkers for immunotherapy resistance in non-small cell lung cancer.非小细胞肺癌免疫治疗耐药的生物标志物
Front Oncol. 2024 Dec 19;14:1489977. doi: 10.3389/fonc.2024.1489977. eCollection 2024.
9
Extracellular vesicles as a promising biomarker resource in liquid biopsy for cancer.细胞外囊泡作为液体活检中一种很有前景的癌症生物标志物来源。
Extracell Vesicles Circ Nucl Acids. 2021 May 13;2(2):148-174. doi: 10.20517/evcna.2021.06. eCollection 2021.
10
Extracellular Vesicles: Diagnostic and Therapeutic Applications in Cancer.细胞外囊泡：在癌症中的诊断与治疗应用
Biology (Basel). 2024 Sep 12;13(9):716. doi: 10.3390/biology13090716.
帕博利珠单抗对比化疗用于 PD-L1 阳性非小细胞肺癌。
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
4
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.肌肉浸润性和转移性膀胱癌患者循环肿瘤细胞（CTC）的程序性死亡配体1（PD-L1）特征分析
BMC Cancer. 2016 Sep 22;16(1):744. doi: 10.1186/s12885-016-2758-3.
5
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab.监测接受 PD-1 抑制剂 Nivolumab 治疗的非小细胞肺癌患者中 PD-L1 阳性循环肿瘤细胞。
Sci Rep. 2016 Aug 24;6:31726. doi: 10.1038/srep31726.
6
The biology and function of exosomes in cancer.外泌体在癌症中的生物学特性与功能
J Clin Invest. 2016 Apr 1;126(4):1208-15. doi: 10.1172/JCI81135.
7
Microsatellite Instability as a Biomarker for PD-1 Blockade.微卫星不稳定性作为 PD-1 阻断的生物标志物。
Clin Cancer Res. 2016 Feb 15;22(4):813-20. doi: 10.1158/1078-0432.CCR-15-1678.
8
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
9
The exosomes in tumor immunity.肿瘤免疫中的外泌体
Oncoimmunology. 2015 Apr 2;4(9):e1027472. doi: 10.1080/2162402X.2015.1027472. eCollection 2015 Sep.
10
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.癌症免疫学。突变图谱决定非小细胞肺癌对程序性死亡受体1（PD-1）阻断治疗的敏感性。
Science. 2015 Apr 3;348(6230):124-8. doi: 10.1126/science.aaa1348. Epub 2015 Mar 12.